Subscribe
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Melanoma MMinutes
Melanoma
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
By
William King
Melanoma
TON - October 2021 Vol 14, No 5
The addition of the lymphocyte activation gene-3 (
LAG-3
)-blocking antibody relatlimab to nivolumab (Opdivo) led to significantly longer progression-free survival (PFS) compared with nivolumab alone in previously untreated patients with advanced melanoma, according to results of the phase 3 RELATIVITY-047 clinical trial presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Read More ›
Tebentafusp Significantly Extends Survival for Patients with Metastatic Uveal Melanoma
Melanoma
TON - August 2021 Vol 14, No 4
Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial.
Read More ›
Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases
Melanoma
Web Exclusives
The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with
BRAF
V
600
-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high.
Read More ›
Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease
Melanoma
Web Exclusives
The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma.
Read More ›
Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media
Melanoma
Web Exclusives
A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers.
Read More ›
Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma
Melanoma
Web Exclusives
In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months.
Read More ›
Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma
Melanoma
Web Exclusives
Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of
BRAF
status.
Read More ›
Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma
Melanoma
Web Exclusives
BRAF/MEK
-targeted therapy rechallenge in patients with
BRAF
-mutation–positive advanced melanoma whose disease progress on first-line
BRAF
-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients.
Read More ›
Immune-Related Adverse Events Occurring After 2 Years of Anti–PD-1 Therapy Are Common
Melanoma
Web Exclusives
In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment.
Read More ›
CheckMate-238 Update: Nivolumab Improves 4-Year Relapse-Free Survival in Patients with Advanced Melanoma
Melanoma
Web Exclusives
Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION